Qrons Inc.

Overview

• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersLong Island City, New York¹
• Incorporated inWY²
• Business address28-10 Jackson Avenue, #26N, Long Island City, Ny 11101²
• Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

General . The Company was incorporated under the laws of the State of Wyoming on August 22, 2016, as BioLabMart Inc. and changed its corporate name to Qrons Inc. on August 8, 2017. Until the acquisition of First Person, the Company was a biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria.⁴ From its latest annual report

Corporate structure

Qrons Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Qrons Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Properties, in its own words

The Company’s principal executive office is located at 611 N. Brand Boulevard, Suite 1300, Glendale, California 91203, for which we pay a monthly rental of $100. We believe that this space is adequate for our current needs.

Item 2 of the 10-K filed Apr 16, 2025.⁴

Leadership

Who has led Qrons Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJonah Meer Jun 19, 2017 to Dec 22, 2022¹³
• PresidentIdo Merfeld Jun 20, 2017 to Dec 22, 2022¹⁴
• Chief financial officerJonah Meer Jun 19, 2017 to Dec 22, 2022¹³
• Chief operating officerJohn N. Bonfiglio Jul 2, 2019 to Jul 2, 2019¹⁵

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• First Person Inc. Delaware, USA³
• First Person Ltd. Alberta, Canada³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• BIOLABMART INC.Nov 3, 2016 to Jul 18, 2017²

Timeline

1. Aug 14, 20268-K Results of operations¹⁶
2. Apr 6, 20268-K Regulation FD disclosure¹⁷
3. Dec 19, 20258-K Regulation FD disclosure¹⁸
4. Jul 10, 20258-K Regulation FD disclosure¹⁹
5. Apr 1, 20258-K Change of auditor²⁰
6. Mar 26, 20258-K Change of auditor²¹
7. Feb 5, 20258-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares²²
8. Jan 21, 20258-K Entered a material agreement; Bylaws or fiscal year changed²³
9. Oct 22, 20248-K Entered a material agreement; Unregistered sale of shares²⁴
10. Nov 6, 20238-K Change of auditor²⁵
11. Jul 24, 20238-K Entered a material agreement; Ended a material agreement; New debt or obligation²⁶
12. Jun 19, 2017New chief executive Jonah Meer becomes CEO¹³

Calendar

When it reported results

1. Aug 14, 2026Reported quarterly or annual results¹⁶

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

44 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 11 major events, 4 insider forms, 15 other. The latest 20:

1. Aug 14, 202615-12G EDGAR
2. Aug 14, 20268-K EDGAR
3. Apr 6, 20268-K EDGAR
4. Dec 19, 20258-K EDGAR
5. Jul 10, 20258-K EDGAR
6. May 15, 2025NT 10-Q EDGAR
7. Apr 16, 202510-K EDGAR
8. Apr 1, 20258-K EDGAR
9. Mar 31, 2025NT 10-K EDGAR
10. Mar 26, 20258-K EDGAR
11. Feb 6, 2025SC 14F1 EDGAR
12. Feb 5, 20258-K EDGAR
13. Jan 21, 20258-K EDGAR
14. Nov 8, 202410-Q EDGAR
15. Oct 22, 20248-K EDGAR
16. Aug 16, 202410-Q EDGAR
17. Aug 14, 2024NT 10-Q EDGAR
18. May 15, 202410-Q EDGAR
19. Apr 15, 202410-K EDGAR
20. Apr 1, 2024NT 10-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Qrons Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARQrons Inc.¹
• CIK0001689084
• Employer ID (EIN)81-3623646⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inWyoming⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address28-10 Jackson Avenue, #26N, Long Island City, NY 11101¹
• Phone212-945-2080¹
• Shares outstanding17,914,999 shares as of Apr 11, 2025⁴
• Public float$881.4K as of Jun 30, 2024⁴
• AuditorLAO PROFESSIONALS, Lagos, Nigeria PCAOB ID 7057; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceNov 3, 2016¹
• Filings121 in all: 8-K (32), 10-Q (24), 4 (12), 10-K (8), 424B3 (4), D (4), EFFECT (4), SC 13D/A (4)¹
  All 24 form types

  3 (3), CORRESP (3), S-1/A (3), CT ORDER (2), NT 10-K (2), NT 10-Q (2), POS AM (2), S-1 (2), SC 13D (2), UPLOAD (2), 15-12G (1), 8-A12G (1), AW (1), DEF 14C (1), PRE 14C (1), SC 14F1 (1)

• Latest filingsAnnual report (10-K) Apr 16, 2025
  Quarterly report (10-Q) Nov 8, 2024
  Latest 8-K (8-K) Aug 14, 2026

Risk factors and legal proceedings

Legal proceedings

There are no pending legal proceedings to which we are a party or in which any director, officer or affiliate of ours, any owner of record or beneficially of more than 5% of any class of our voting securities, or security holder is a party adverse to us or has a material interest adverse to us.

The opening of Item 3, Legal Proceedings.⁴